Title |
The first 100 patients in the SUN(^_^)D trial (strategic use of new generation antidepressants for depression): examination of feasibility and adherence during the pilot phase
|
---|---|
Published in |
Trials, June 2012
|
DOI | 10.1186/1745-6215-13-80 |
Pubmed ID | |
Authors |
Shinji Shimodera, Tadashi Kato, Hirotoshi Sato, Kazuhira Miki, Yoshihiro Shinagawa, Masaki Kondo, Hirokazu Fujita, Ippei Morokuma, Yoshio Ikeda, Tatsuo Akechi, Norio Watanabe, Mitsuhiko Yamada, Masatoshi Inagaki, Naohiro Yonemoto, Toshi A Furukawa, For the SUN(^_^)D Investigators |
Abstract |
Initial glitches and unexpected inconsistencies are unavoidable in the early stage of a large, multi-centre trial. Adaptive modifications of the trial's protocol and operational procedures to ensure its smooth running are therefore imperative. We started a large pragmatic, multi-centre, assessor-blinded, 25-week trial to investigate the optimal first- and second-line treatments for untreated episodes of nonpsychotic major depression in 2010 [Strategic Use of New generation antidepressants for Depression, abbreviated SUN(^_^)D] and would like to herein report an examination of the trial's feasibility and adherence among the first 100 participants. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 1% |
Unknown | 77 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 17 | 22% |
Student > Ph. D. Student | 9 | 12% |
Student > Master | 9 | 12% |
Student > Bachelor | 8 | 10% |
Professor | 6 | 8% |
Other | 10 | 13% |
Unknown | 19 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 24 | 31% |
Psychology | 8 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 8 | 10% |
Social Sciences | 4 | 5% |
Agricultural and Biological Sciences | 3 | 4% |
Other | 10 | 13% |
Unknown | 21 | 27% |